Cardiology

Your Article Summary

See Latest Articles

Vanoxerine: Cellular Mechanism of a New Antiarrhythmic
Journal of Cardiovascular Electrophysiology, 10/27/09

Lacerda AE et al. – Vanoxerine is a potent blocker of cardiac hERG, Na and Ca channels; block is strongly frequency–dependent especially for Na and Ca channels; and transmural dispersion of ventricular repolarization is unaffected. The multichannel block and repolarization uniformity resemble the effects of amiodarone, the exemplar atrial fibrillation drug. Vanoxerine is a completely different chemical and has none of amiodarone's toxic effects. Vanoxerine has characteristics of a potentially effective and safe antiarrhythmic.

Today in Arrhythmias/EP...keeping you current

Receive free subspecialty "5-minute updates" via email

Acute Coronary Syndromes: Diagnosis and Management, Part I
Mayo Clinic Proceedings, 10/05/09

New Anticoagulants in Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 10/02/09

Acute medical management of the non-ST-segment elevation acute coronary syndromes (NSTE-ACS) in older patients
Archives of Gerontology and Geriatrics, 10/14/09

See All of Arrhythmias/EP

Today in Clinical Pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

New Anticoagulants in Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 10/02/09

Effectiveness of Two-Year Clopidogrel + Aspirin in Abolishing the Risk of Very Late Thrombosis After Drug-Eluting Stent Implantation (from the TYCOON [Two-Year ClOpidOgrel Need] Study)
The American Journal of Cardiology, 11/05/09

Systematic Review: Comparative Effectiveness and Harms of Combination Therapy and Monotherapy for Dyslipidemia
Annals of Internal Medicine, 11/03/09

See All of Clinical Pharmacology